GlassScriptPhysician profile
Christie S Thomas
NPI 1073725875
$12,396.38
in general payments reported to CMS, 2019-2025
36 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,707 · 2020: $843 · 2021: $1,209 · 2022: $1,766 · 2023: $2,247 · 2024: $2,243 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,859 · Education: $12.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,858.54 |
| Education | $12.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,127.60 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,349.27 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $1,173.15 | 2019-2025 | Evenity, Enbrel, Tavneos |
| Novartis Pharmaceuticals Corporation | $1,114.92 | 2019-2025 | |
| Janssen Biotech, INC. | $986.97 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Glaxosmithkline, LLC. | $882.84 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $866.44 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals LP | $495.35 | 2021-2025 | Saphnelo |
| Pfizer INC. | $483.24 | 2019-2025 | |
| Genentech USA, INC. | $225.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.62 | 2020-2025 | Ofev |
| Fresenius Kabi USA, LLC | $209.47 | 2023-2024 | Idacio |
| Horizon Therapeutics Plc | $201.12 | 2019-2022 | |
| Celgene Corporation | $160.60 | 2019 | |
| Radius Health, INC. | $113.42 | 2020-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $113.42 | 2024 | Impella |
| Mallinckrodt Hospital Products INC. | $74.02 | 2022-2023 | Acthar |
| Scilex Pharmaceuticals INC. | $61.95 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $60.64 | 2019 | |
| Genzyme Corporation | $48.96 | 2025 | |
| Mallinckrodt Enterprises LLC | $48.88 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $47.30 | 2021-2023 | Opsumit, Uptravi |
| Aurinia Pharma U.S., INC. | $42.44 | 2022-2025 | Lupkynis |
| Lilly USA, LLC | $41.26 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $39.51 | 2021 | |
| Janssen Pharmaceuticals, INC | $38.46 | 2025 | Tremfya |
| Mylan Institutional INC. | $24.02 | 2023 | Hulio |
| Organon LLC | $21.54 | 2023 | Hadlima, Renflexis |
| Kiniksa Pharmaceuticals International, Plc | $21.11 | 2024 | Arcalyst |
| Octapharma USA, INC. | $20.79 | 2023 | Panzyga |
| Sobi, INC | $16.62 | 2025 | |
| Assertio Therapeutics, INC. | $16.60 | 2019 | |
| Tersera Therapeutics LLC | $14.81 | 2024 | Quzyttir |
| Kiniksa Pharmaceuticals, LTD. | $14.40 | 2022 | |
| Celltrion USA INC. | $12.86 | 2023 | Yuflyma |
| Medexus Pharma, INC. | $11.49 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christie Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.